#### Edgar Filing: HAEMONETICS CORP - Form 8-K

### HAEMONETICS CORP Form 8-K July 29, 2004

\_\_\_\_\_\_

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 29, 2004

#### HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts 1-10730 04-2882273

(State or other jurisdiction (Commission File (IRS Employer of incorporation) Number) Identification No.)

400 Wood Road Braintree, MA

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (781) 848-7100

(Former name or former address if changed since last report)

- Item. 7 FINANCIAL STATEMENTS AND EXHIBITS
  - (c) Exhibits

99.1: Press Release of Haemonetics Corporation dated July 29, 2004

Item. 12 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On July 29, 2004, Haemonetics Corporation (the "Company") issued a press release announcing financial results for the first quarter ended July 3, 2004. A copy of the release is furnished with this report as exhibit 99.1.

The information in this current report on Form 8-K and the exhibit attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

SIGNATURES

## Edgar Filing: HAEMONETICS CORP - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(Registrant)

Date: July 29, 2004 By: /s/ Ronald J. Ryan

\_\_\_\_\_

Ronald J. Ryan, Vice President and Chief

Financial Officer

2

EXHIBIT INDEX

Exhibit No. Subject Matter

99.1 Press Release of Haemonetics Corporation

dated July 29, 2004.

3